A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease



Status:Completed
Conditions:Alzheimer Disease, Cognitive Studies
Therapuetic Areas:Neurology, Psychiatry / Psychology
Healthy:No
Age Range:40 - Any
Updated:4/21/2016
Start Date:August 2008
End Date:April 2012

Use our guide to learn which trials are right for you!

A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease

Based on prior published pilot studies, the investigators have initiated a larger,
multi-site placebo-controlled clinical trial with Alzheimer's disease (AD) patients and
individuals diagnosed with Mild Cognitive Impairment (MCI), with the hopes of (1) confirming
(or denying) the above promising clinical findings, and (2) determining whether or not our
formulation can delay MCI "conversion" to AD.

Preclinical studies with mouse models of of age-related neurodegeneration led us to develop
a Nutriceutical Formulation ("NF") consisting of 6 over-the-counter vitamins and
nutriceuticals, that buffers multiple facets of Alzheimer's disease (AD), including (1)
reducing presenilin expression, gamma-secretase activity, Abeta generation and tau
phosphorylation, (2) buffering homocysteine and Abeta-induced oxidative damage, (3) reducing
aggression, (4) increasing acetylcholine production and improving/maintaining cognitive
performance.

A 1-year, open-label trial with NF with mild to moderate AD patients demonstrate improvement
in cognitive performance (Dementia Rating Scale, Clock-drawing) within 3-6 months.
Caregivers reported maintenance of daily performance and improved mood (ADCS-Activities of
Daily Living and NeuroPsychiatric Inventory). A placebo-controlled study with moderate to
late-stage AD indicates delayed cognitive decline and maintenance of daily activities. No
adverse events were reported.

A multi-site trial with >90 individuals aged 45-73 without dementia indicated that NF
statistically improved executive function (Trails B-A) vs. placebo within 3 months, which
increased further at 6 months. The placebo group demonstrated identical improvement in a
3-month open-label extension. Following NF withdrawal, participants returned to baseline;
statistically-significant improvement was restored once NF was individuals resumed.

We have initiated a larger, multi-site placebo-controlled clinical trial with AD patients
and individuals diagnosed with Mild Cognitive Impairment (MCI), with the hopes of (1)
confirming (or denying) the above promising clinical findings, and (2) determining whether
or not our formulation can delay MCI "conversion" to AD.

Inclusion Criteria:

- Clinical diagnosis of Alzheimer's disease or Mild Cognitive Impairment

- must be able to swallow pills

Exclusion Criteria:

- known or suspected bipolar disorder
We found this trial at
8
sites
Baltimore, Maryland 20742
(301) 405-1000
University of Maryland As a globally-connected university offering a world-class education, the University of Maryland...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Ayer, Massachusetts 01432
?
mi
from
Ayer, MA
Click here to add this to my saved trials
Groton, Massachusetts 01459
?
mi
from
Groton, MA
Click here to add this to my saved trials
Lawrence, Massachusetts 01841
?
mi
from
Lawrence, MA
Click here to add this to my saved trials
Layton, Utah 84040
?
mi
from
Layton, UT
Click here to add this to my saved trials
Lowell, Massachusetts 01854
?
mi
from
Lowell, MA
Click here to add this to my saved trials
Mt. Arlington, New Jersey 07856
?
mi
from
Mt. Arlington, NJ
Click here to add this to my saved trials
Naples, Florida 34102
?
mi
from
Naples, FL
Click here to add this to my saved trials